整合酶链转移抑制剂与直接抗病毒药物时代HIV及HIV/丙型肝炎病毒共感染患者肝移植后生存改善
回顾性分析比较整合酶链转移抑制剂(INSTI)与直接抗病毒药物(DAA)获批前后成人HIV单感染(n=246)和HIV/丙型肝炎病毒(HCV)共感染(n=286)肝移植受者的死亡率。HIV单感染者在INSTI前后生存无显著改善(aHR 0.70,95%CI .36-1.34);HIV/HCV共感染者在DAA时代1年死亡率较前DAA时代降低47%(aHR 0.53,95%CI .31-9.2)。与无HIV或HCV受者相比,INSTI时代HIV单感染者及DAA时代HIV/HCV共感染者生存相当。
要点
- HIV单感染肝移植受者INSTI前后生存无显著改善(aHR 0.70,95%CI .36-1.34)。
- HIV/HCV共感染受者DAA时代1年死亡率较前DAA时代降低47%(aHR 0.53,95%CI .31-9.2)。
- INSTI时代HIV单感染者及DAA时代HIV/HCV共感染者生存与无HIV或HCV受者相当。
核心结论
- HIV单感染和HIV/HCV共感染患者肝移植后生存随INSTI和DAA治疗的应用而改善,提示肝移植在这些人群中变得更安全。
研究设计与样本
- 回顾性分析纳入接受肝移植的成人HIV单感染者246例和HIV/HCV共感染者286例,比较INSTI获批前后HIV单感染者及DAA获批前后HIV/HCV共感染者的死亡率。
- 次要分析将不同时代的结局与倾向性评分匹配的无HIV或HCV感染肝移植受者对照队列进行比较。
主要发现
- HIV单感染肝移植受者INSTI前后生存无显著改善(aHR 0.70,95%CI .36-1.34)。
- HIV/HCV共感染受者DAA时代1年死亡率较前DAA时代降低47%(aHR 0.53,95%CI .31-9.2)。
- 与无HIV或HCV受者相比,HIV单感染受者前INSTI时代死亡率较高,INSTI时代两组生存相当。
- HIV/HCV共感染受者DAA时代与无HCV或HIV受者生存相当。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: People with human immunodeficiency virus (HIV) with and without hepatitis C virus (HCV) coinfection had poor outcomes after liver transplant (LT). Integrase strand transfer inhibitors (INSTIs) and direct-acting antivirals (DAAs) have changed the treatment landscape for HIV and HCV, respectively, but their impact on LT outcomes remains unclear. METHODS: This retrospective analysis of adults with HIV monoinfection (n = 246) and HIV/HCV coinfection (n = 286) who received LT compared mortality in patients with HIV who received LT before versus after approval of INSTIs and in patients with HIV/HCV coinfection who received LT before versus after approval of DAAs. In secondary analysis, we compared the outcomes in the different eras with those of propensity score-matched control cohorts of LT recipients without HIV or HCV infection. RESULTS: LT recipients with HIV monoinfection did not experience a significant improvement in survival between the pre-INSTI and INSTI recipients with HIV (adjusted hazard ratio [aHR], 0.70 [95% confidence interval {CI}, .36-1.34]). However, recipients with HIV/HCV coinfection in the DAA era had a 47% reduction (aHR, 0.53 [95% CI, .31-9.2] in 1-year mortality compared with coinfected recipients in the pre-DAA era. Compared to recipients without HIV or HCV, HIV-monoinfected recipients had higher mortality during the pre-INSTI era, but survival was comparable between groups during the INSTI era. HIV/HCV-coinfected recipients also experienced comparable survival during the DAA era compared to recipients without HCV or HIV. CONCLUSIONS: Post-LT survival for people with HIV monoinfection and HIV/HCV coinfection has improved with the introduction of INSTI and DAA therapy, suggesting that LT has become safer in these populations.
引用
- Jacob JS, Shaikh A, Goli K, et al. Improved Survival After Liver Transplantation for Patients With Human Immunodeficiency Virus (HIV) and HIV/Hepatitis C Virus Coinfection in the Integrase Strand Transfer Inhibitor and Direct-Acting Antiviral Eras. Clin Infect Dis. 2023. PMID: 36221143. doi:10.1093/cid/ciac821
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。